ATE326956T1 - Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität - Google Patents
Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizitätInfo
- Publication number
- ATE326956T1 ATE326956T1 AT98962011T AT98962011T ATE326956T1 AT E326956 T1 ATE326956 T1 AT E326956T1 AT 98962011 T AT98962011 T AT 98962011T AT 98962011 T AT98962011 T AT 98962011T AT E326956 T1 ATE326956 T1 AT E326956T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- aminothiole
- kidney diseases
- drug toxicity
- treat nerve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/987,550 US5994409A (en) | 1997-12-09 | 1997-12-09 | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE326956T1 true ATE326956T1 (de) | 2006-06-15 |
Family
ID=25533362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98962011T ATE326956T1 (de) | 1997-12-09 | 1998-12-09 | Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität |
Country Status (13)
Country | Link |
---|---|
US (7) | US5994409A (de) |
EP (2) | EP1537861A3 (de) |
JP (2) | JP2001525359A (de) |
CN (1) | CN1161113C (de) |
AT (1) | ATE326956T1 (de) |
AU (1) | AU739068B2 (de) |
BR (1) | BR9813524A (de) |
CA (1) | CA2313089C (de) |
DE (1) | DE69834658T2 (de) |
DK (1) | DK1039887T3 (de) |
ES (1) | ES2260857T3 (de) |
PT (1) | PT1039887E (de) |
WO (1) | WO1999029312A1 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU741439B2 (en) * | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
US6573253B2 (en) | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6384259B1 (en) * | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
AU2000239101A1 (en) * | 2000-03-22 | 2001-10-03 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
JP5242877B2 (ja) * | 2000-04-26 | 2013-07-24 | オレゴン ヘルス アンド サイエンス ユニバーシティー | チオールをベースとする化学保護剤の投与 |
US7655694B2 (en) * | 2000-06-14 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
EP1365803A2 (de) * | 2000-08-30 | 2003-12-03 | Oregon Health and Science University | Chemoschützende verbindung zur reduzierung der gastrischen toxizität von wirkstoffen |
ATE316786T1 (de) * | 2000-11-22 | 2006-02-15 | Rxkinetix Inc | Behandlung von mukositis |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
HUP0500642A2 (hu) * | 2001-09-24 | 2005-11-28 | Tosk, Inc. | Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra |
CN100391941C (zh) * | 2001-12-07 | 2008-06-04 | 海门慧聚药业有限公司 | 一种胺基硫醇及其硫代衍生物 |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
US7981928B2 (en) * | 2002-09-05 | 2011-07-19 | Nanodynamics, Inc. | Chemotherapy method using x-rays |
AU2003285128A1 (en) * | 2002-10-31 | 2004-05-25 | Oregon Health And Science University | Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
KR20050105451A (ko) * | 2003-02-03 | 2005-11-04 | 네오팜 인코포레이티드 | 안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제 |
US20040198841A1 (en) * | 2003-03-13 | 2004-10-07 | Oregon Health & Science University | Use of thiol-based compositions in ameliorating mucosal injury |
US8580321B2 (en) * | 2003-12-02 | 2013-11-12 | The Cleveland Clinic Foundation | Method for reducing the effects of chemotherapy using flagellin related polypeptides |
US20050187608A1 (en) * | 2004-02-24 | 2005-08-25 | O'hara Michael D. | Radioprotective compound coating for medical devices |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
WO2006044738A2 (en) * | 2004-10-18 | 2006-04-27 | Maroon Biotech Corporation | Methods and compositions for treatment of free radical injury |
US20070082858A1 (en) * | 2004-12-21 | 2007-04-12 | Oregon Health & Science University | Methods and compositions for the prevention of toxic side effects of aminoglycoside medications |
US8007812B2 (en) | 2004-12-22 | 2011-08-30 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
EP1954292B1 (de) * | 2005-11-28 | 2014-05-07 | Verrow Pharmaceuticals, Inc. | Zusammensetzungen zur minderung von nephrotoxizität und verfahren zu ihrer anwendung |
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
US9585849B2 (en) * | 2006-04-17 | 2017-03-07 | The Burlington Hc Research Group, Inc. | Broad spectrum antiviral and methods of use |
EP2010166B1 (de) * | 2006-04-17 | 2013-11-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Antiretrovirale mittel aus organischem disulfiden |
US8138227B2 (en) * | 2006-07-06 | 2012-03-20 | Trustees Of Dartmouth College | Method for inhibiting or reversing non-enzymatic glycation |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
WO2008060441A2 (en) * | 2006-11-09 | 2008-05-22 | Scidose Llc | Stable amifostine liquid concentrate |
WO2008119032A1 (en) | 2007-03-27 | 2008-10-02 | Perscitus Biosciences, Llc | Compositions and methods for protecting cells from toxic exposures |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
JP2011504924A (ja) * | 2007-11-28 | 2011-02-17 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 放射線または化学療法により誘導された組織の損傷の処置のための方法 |
EP2252246B1 (de) * | 2008-03-14 | 2014-06-18 | Bionumerik Pharmaceuticals, Inc. | Chemoprotektive verfahren und zusammensetzungen |
ES2412237T3 (es) | 2008-08-01 | 2013-07-10 | Cleveland Biolabs, Inc. | Métodos para tratar lesiones por reperfusión |
CN101347412B (zh) * | 2008-09-02 | 2011-07-27 | 大连美罗药业股份有限公司 | 三水合氨磷汀结晶冻干制剂及其制备方法 |
KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
US20140050728A1 (en) * | 2011-01-28 | 2014-02-20 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications |
TWI568453B (zh) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | 具有螯合型複合微胞之藥物載體及其應用 |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
WO2014204854A1 (en) * | 2013-06-18 | 2014-12-24 | Aminomdix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
JP6940916B2 (ja) | 2014-07-30 | 2021-09-29 | ゲノム プロテクション,インコーポレイテッド | フラジェリン組成物および使用 |
WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
CN107753490B (zh) * | 2017-11-19 | 2018-07-27 | 宋在明 | 一种治疗肿瘤放疗所致口腔黏膜炎的透皮给药制剂 |
AU2020293522B2 (en) * | 2019-06-13 | 2024-01-25 | Shanghai Kechow Pharma, Inc. | Use of aminothiol compounds as cerebral nerve or heart protective agent |
CN114712350B (zh) * | 2021-12-28 | 2024-04-12 | 中国医学科学院放射医学研究所 | Dttz在制备预防、治疗化疗损伤药物中的应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892824A (en) * | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
US4424216A (en) * | 1979-07-31 | 1984-01-03 | The Rockefeller University | Method for the reduction of mucin viscosity |
US4742050B1 (en) | 1982-08-17 | 1994-06-28 | Alpha Therapeutic Corp | Sensitization of hypoxic tumor cells and control of growth thereof |
US4656034A (en) | 1985-05-20 | 1987-04-07 | Survival Technology, Inc. | Absorption enhancing agents |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
NZ224263A (en) | 1987-04-15 | 1990-08-28 | Freezone Pty Ltd | Tyre bead-rim breaker |
US5091180A (en) | 1987-11-20 | 1992-02-25 | Administrators Of The Tulane Educational Fund | Protection against rhabdomyolysis-induced nephrotoxicity |
WO1989005637A1 (en) * | 1987-12-22 | 1989-06-29 | U.S. Bioscience | Improving toxicity profiles in chemotherapy |
US5112954A (en) | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
JPH04505760A (ja) * | 1989-05-24 | 1992-10-08 | ユー・エス・バイオサイエンス | Aztの副作用および毒性からの保護方法 |
US5167947A (en) | 1989-10-26 | 1992-12-01 | Southwest Research Institute | Enhancement of absorption of radioprotective drugs |
US5217964A (en) | 1991-01-23 | 1993-06-08 | Merrell Dow Pharmaceuticals Inc. | Polyamine thiols as radioprotective agents |
US5554655A (en) * | 1991-09-30 | 1996-09-10 | Jess G. Thoene | Method of treating HIV infection |
US5567686A (en) * | 1992-03-13 | 1996-10-22 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5488042A (en) * | 1992-03-13 | 1996-01-30 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5869338A (en) * | 1992-03-13 | 1999-02-09 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
US5618823A (en) | 1992-06-24 | 1997-04-08 | Boehringer Mannheim Italia S.P.A. | Glutathione as chemoprotective agent |
US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
SG47101A1 (en) * | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
DE4234257A1 (de) * | 1992-10-10 | 1994-04-14 | Roehm Gmbh | Verfahren zur Herstellung von Thiol(meth)acrylaten |
HUT74005A (en) | 1993-02-23 | 1996-10-28 | Merrell Pharma Inc | Polyamine derivatives as radioprotective agents and pharmaceutical compositions containing them |
US5824664A (en) * | 1993-03-26 | 1998-10-20 | U.S. Bioscience, Inc. | Suppression of HIV expression by organic thiophosphate |
CA2124021A1 (en) | 1993-05-21 | 1994-11-22 | John Samonides Sr. | Adhesive for labels and the like |
ES2119203T3 (es) | 1993-05-26 | 1998-10-01 | Merrell Pharma Inc | Derivados de poliamina n-alquiltio utilizados como agentes radioprotectores. |
CA2099070A1 (en) | 1993-06-23 | 1994-12-24 | Nelson Mak | Process and apparatus for deinking wastepaper with molten fatty acid |
US5467947A (en) * | 1994-04-08 | 1995-11-21 | Metra Electronics Corporation | Mounting kit for mounting one of several types of audio equipment in an automotive dashboard |
US5846958A (en) * | 1995-02-17 | 1998-12-08 | U.S. Bioscience, Inc. | Methods of using aminothiols to promote hematopoietic progenitor cell growth |
GB9504995D0 (en) * | 1995-03-11 | 1995-04-26 | Zeneca Ltd | Compositions |
US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5974409A (en) * | 1995-08-23 | 1999-10-26 | Microsoft Corporation | System and method for locating information in an on-line network |
WO1997011666A2 (en) * | 1995-09-25 | 1997-04-03 | Samir Chachoua | Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
US6110891A (en) | 1996-06-21 | 2000-08-29 | Alizyme Therapeutics Ltd. | Lectin compositions and uses thereof |
US5866591A (en) | 1996-09-11 | 1999-02-02 | Glaxo Wellcome Inc. | Stable formulations of remifentanil |
US6051563A (en) * | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
US6573253B2 (en) * | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US5919934A (en) | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
FR2761606B1 (fr) | 1997-04-08 | 1999-05-14 | Cird Galderma | Utilisation de derives aminothiolesters dans le domaine pharmaceutique |
US6284259B1 (en) * | 1997-11-12 | 2001-09-04 | The Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
WO1999030705A1 (en) | 1997-12-16 | 1999-06-24 | William Darwin Garner | Reduction of uv induced skin cancer by topical amines |
JPH11240252A (ja) | 1997-12-22 | 1999-09-07 | Tdk Corp | 光記録媒体 |
US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
US6384259B1 (en) * | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
US6054622A (en) | 1998-12-18 | 2000-04-25 | Alliedsignal Inc | Aromatic hydroxythiol synthesis using diazonium salts |
US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
US6489312B1 (en) * | 1999-06-15 | 2002-12-03 | Medimmune Oncology, Inc. | Pharmaceutical formulations comprising aminoalkyl phosphorothioates |
-
1997
- 1997-12-09 US US08/987,550 patent/US5994409A/en not_active Expired - Lifetime
-
1998
- 1998-12-09 DE DE69834658T patent/DE69834658T2/de not_active Expired - Lifetime
- 1998-12-09 EP EP05003650A patent/EP1537861A3/de not_active Withdrawn
- 1998-12-09 AU AU17184/99A patent/AU739068B2/en not_active Expired
- 1998-12-09 AT AT98962011T patent/ATE326956T1/de active
- 1998-12-09 CN CNB988135442A patent/CN1161113C/zh not_active Expired - Fee Related
- 1998-12-09 PT PT98962011T patent/PT1039887E/pt unknown
- 1998-12-09 CA CA2313089A patent/CA2313089C/en not_active Expired - Fee Related
- 1998-12-09 JP JP2000523983A patent/JP2001525359A/ja active Pending
- 1998-12-09 WO PCT/US1998/026096 patent/WO1999029312A1/en active IP Right Grant
- 1998-12-09 ES ES98962011T patent/ES2260857T3/es not_active Expired - Lifetime
- 1998-12-09 BR BR9813524-4A patent/BR9813524A/pt not_active Application Discontinuation
- 1998-12-09 EP EP98962011A patent/EP1039887B1/de not_active Expired - Lifetime
- 1998-12-09 DK DK98962011T patent/DK1039887T3/da active
-
1999
- 1999-10-28 US US09/429,290 patent/US6586476B1/en not_active Expired - Lifetime
-
2002
- 2002-05-03 US US10/137,686 patent/US7105575B2/en not_active Expired - Lifetime
-
2005
- 2005-10-25 US US11/258,335 patent/US20060040903A1/en not_active Abandoned
-
2006
- 2006-03-09 JP JP2006064774A patent/JP2006188532A/ja active Pending
- 2006-08-09 US US11/501,949 patent/US20060270636A1/en not_active Abandoned
-
2010
- 2010-12-08 US US12/963,574 patent/US20110166108A1/en not_active Abandoned
-
2012
- 2012-11-29 US US13/689,652 patent/US20130090312A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999029312A1 (en) | 1999-06-17 |
US20060040903A1 (en) | 2006-02-23 |
US7105575B2 (en) | 2006-09-12 |
EP1039887B1 (de) | 2006-05-24 |
US5994409A (en) | 1999-11-30 |
JP2001525359A (ja) | 2001-12-11 |
EP1537861A3 (de) | 2005-06-15 |
US20060270636A1 (en) | 2006-11-30 |
US20130090312A1 (en) | 2013-04-11 |
US6586476B1 (en) | 2003-07-01 |
ES2260857T3 (es) | 2006-11-01 |
CN1161113C (zh) | 2004-08-11 |
EP1039887A1 (de) | 2000-10-04 |
US20020132795A1 (en) | 2002-09-19 |
EP1537861A2 (de) | 2005-06-08 |
DE69834658D1 (de) | 2006-06-29 |
JP2006188532A (ja) | 2006-07-20 |
BR9813524A (pt) | 2002-02-19 |
PT1039887E (pt) | 2006-10-31 |
AU739068B2 (en) | 2001-10-04 |
CA2313089A1 (en) | 1999-06-17 |
DK1039887T3 (da) | 2006-09-11 |
US20110166108A1 (en) | 2011-07-07 |
CA2313089C (en) | 2010-10-12 |
CN1283994A (zh) | 2001-02-14 |
EP1039887A4 (de) | 2003-01-15 |
DE69834658T2 (de) | 2007-05-03 |
AU1718499A (en) | 1999-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE326956T1 (de) | Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität | |
WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
MXPA03003960A (es) | Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos. | |
TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
NO20101190L (no) | Anvendelse av buprenorfin i fremstillingen av et medikament | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
ATE170077T1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
DE69819110D1 (de) | Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus | |
WO2005011572A3 (en) | Combination of drugs for the treatment of neoplasms | |
DE60218843D1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
ATE156359T1 (de) | Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis | |
ATE222109T1 (de) | Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten | |
ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
DE69912304D1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
ATE120447T1 (de) | Polyamin-derivate als antineoplastische mittel. | |
ATE232739T1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1039887 Country of ref document: EP |